MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 545
- Registration Number
- NCT01601119
- Locations
- 🇬🇧
Please contact the, Merck KGaA Communication Center for locations, United Kingdom
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina
Completed
- Conditions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 68
- Registration Number
- NCT01582334
- Locations
- 🇦🇷
For Recruiting Locations in Argentina, Please Contact The Merck KGaA Communication Center, Argentina
Cilengitide Imaging Trial in Glioblastoma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1
- Registration Number
- NCT01558687
- Locations
- 🇩🇪
Merck KGaA Communication Center located in, Darmstadt, Germany
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Mexico
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 193
- Registration Number
- NCT01555528
- Locations
- 🇲🇽
For Recruiting Locations in Mexico, Please Contact The Merck KGaA Communication Center, Mexico
Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 80
- Registration Number
- NCT01514370
- Locations
- 🇮🇹
Investigational Site, Naples, Italy
Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Registration Number
- NCT01510522
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 186
- Registration Number
- NCT01508325
- Locations
- 🇨🇳
Merck Serono Investigational Site, Changsha City, China
Tecemotide (L-BLP25) in Rectal Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 124
- Registration Number
- NCT01507103
- Locations
- 🇳🇱
NKI (Nederlands Kanker Instituut), Amsterdam, Netherlands
Pharmacokinetics in Subjects With Renal Impairment
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 32
- Registration Number
- NCT01504165
- Locations
- 🇩🇪
CRS Clincial Research Services Kiel GmbH, Kiel, Germany
🇩🇪For Research Sites contact Merck KGaA Communication Center in, Darmstadt, Germany
A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 174
- Registration Number
- NCT01497197
- Locations
- 🇦🇪
Merck Serono Research Site, Dubai, United Arab Emirates
© Copyright 2024. All Rights Reserved by MedPath